Confirmation of a novel, stable estrogen metabolite, as 5a,6a-epoxy-estrone sulfate in stallion blood by LC-MS/MS.

Overview

• This study confirmed the presence of a previously predicted but unconfirmed estrogen metabolite, 5α,6α-epoxy-estrone sulfate, in stallion blood using advanced mass spectrometry techniques.
• The research provides detailed molecular characterization of this novel metabolite, indicating its stable presence and potential physiological relevance.

Introduction and Background

• Estrogens are steroid hormones important in numerous biological processes, often present in very low concentrations in biological fluids.
• Understanding estrogen metabolism is critical in both physiological and pathological contexts, yet some metabolites remain uncharacterized due to analytical challenges.
• Previous studies suggested the existence of a metabolite identified as 5α,6α-epoxy-estrone sulfate through indirect methods such as radiolabeling, but direct confirmation was lacking.
• Mass spectrometry (MS), particularly liquid chromatography coupled with high-resolution tandem mass spectrometry (LC-HRMS/MS), allows precise molecular identification even at low abundance.

Objectives

• To confirm and structurally characterize the identity of the novel estrogen metabolite 5α,6α-epoxy-estrone sulfate in stallion blood.
• To provide definitive mass spectrometric evidence supporting the predicted molecular structure.
• To show the stability and biological presence of this metabolite in the bloodstream, implying systemic distribution.

Methodology

• Samples were collected from serum of three stallions to ensure reproducibility across individual animals.
• Sample preparation involved liquid-liquid extraction, an effective method to isolate steroid metabolites from biological samples with minimal interference.
• Separation was performed using liquid chromatography to isolate the metabolite among complex serum constituents.
• High-resolution tandem mass spectrometry (LC-HRMS/MS) was employed for accurate mass detection and fragmentation analysis to identify structural features.
• Two LC-QTOF instruments, using quadrupole time-of-flight technology, were employed to confirm findings independently, enhancing robustness of identification.

Findings and Interpretation

• A distinct chromatographic peak corresponding to the suspected metabolite was observed and isolated for analysis.
• MS/MS fragmentation patterns provided key structural information:
  • Precursor ion at m/z 365.5 [M-H] suggested a molecular weight consistent with sulfate conjugation.
  • Fragment ions at m/z 79.9 indicated the presence of a sulfate group (SO₄). Sulfate fragmentation ions are well-known markers in steroid sulfates.
  • Fragment at m/z 285.1 corresponded to an estrone sulfate backbone with an additional oxygen, consistent with an epoxide (5α,6α-epoxy) modification.
• Compared with reference estrone sulfate standards, the metabolite showed differences in fragmentation consistent with the presence of an epoxy group, confirming novelty.
• Other fragment ions further supported the proposed structure, distinguishing it from known estrogen metabolites.
• The consistency across two different instruments and multiple stallion samples validated the metabolite’s identity and stable presence.

Significance and Implications

• Identification in blood circulation implies the metabolite can distribute systemically in the organism, potentially affecting various tissues.
• This novel metabolite’s unique structure could influence biological activity, receptor interactions, or metabolic pathways differently than other estrogens.
• The stable presence suggests it might have physiological roles or could serve as a biomarker in veterinary or human medicine.
• Future research can investigate its metabolic origin, enzymatic pathways responsible for epoxidation and sulfation, and possible roles in health or disease.
• Methodological approach demonstrates the power of LC-HRMS/MS for discovering and confirming novel low-abundance steroid metabolites.

Conclusion

• The study successfully confirms the existence of 5α,6α-epoxy-estrone sulfate in stallion blood, previously only hypothesized.
• This novel, stable estrogen metabolite expands the known diversity of steroid metabolism in equids and potentially other species.
• The findings open avenues for further physiological and pathological exploration of this unique estrogen derivative.